The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis;
pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental …

Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU
and several other countries for the prevention of venous thromboembolism after elective hip …

ESC Guidelines 2372 levels, once the guidelines have been endorsed by the ESC member
societies, and translated into the national language. Implementation programmes are …

Objective Despite extensive use of oral anticoagulation (OAC) in patients with atrial
fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy …

前言心房颤动(房颤) 是临床上最常见的室上性心动过速. 据Framingham 研究提示[1],
人群患病率为0.5% 左右, 且随年龄增长其患病率增高; 60 岁以上的人群中, 其患病率可达6%; …

Background Effectiveness and safety of warfarin is associated with the time in therapeutic
range (TTR) with an international normalised ratio (INR) of 2· 0–3· 0. In the Randomised …

To the Editor: We wish to update our article about the Randomized Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) trial (Sept. 17, 2009, issue). 1 After the database was …

Background and Purpose—The risk of stroke in patients with atrial fibrillation (AF) is not
homogeneous, and various clinical risk factors have informed the development of stroke risk …

Summary Background In the Randomised Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) trial, dabigatran reduced occurrence of both stroke and haemorrhage compared …

BACKGROUND: Vitamin K antagonists have been the standard oral antithrombotic used for
more than a half century for prevention and treatment of thromboembolism. Their limitations …